Cargando…

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers

BACKGROUND: We performed a phase I modified 3 + 3 dose escalation study to evaluate the safety and activity of bevacizumab plus gemcitabine and nab-paclitaxel in patients with advanced solid tumours. METHODS: Patients were given fixed dose gemcitabine plus increasing doses of nab-paclitaxel and beva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sen, Shiraj, Kato, Shumei, Agarwal, Rishi, Piha-Paul, Sarina, Hess, Kenneth, Karp, Daniel, Janku, Filip, Fu, Siqing, Naing, Aung, Pant, Shubham, Falchook, Gerald, Tang, Chad, Wu, Xifeng, Ye, Yuanqing, Tsimberidou, Apostolia, Subbiah, Vivek, Kurzrock, Razelle, Byers, Lauren, Westin, Shannon, Lim, JoAnn, Bean, Stacie, Bass, Allison, Nguyen, Ly, Meric-Bernstam, Funda, Hong, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988803/ https://www.ncbi.nlm.nih.gov/pubmed/29695765 http://dx.doi.org/10.1038/s41416-018-0068-z

Ejemplares similares

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
por: Subbiah, Vivek, et al.
Publicado: (2020)

Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
por: Reilley, Matthew J., et al.
Publicado: (2017)

Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials
por: Sen, Shiraj, et al.
Publicado: (2018)

Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials
por: Subbiah, Ishwaria M., et al.
Publicado: (2015)

Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic
por: Dembla, Vikas, et al.
Publicado: (2018)

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
por: Park, Haeseong, et al.
Publicado: (2016)

BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy
por: Said, Rabih, et al.
Publicado: (2013)

Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population
por: Wheler, Jennifer, et al.
Publicado: (2013)

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer
por: Falchook, Gerald S., et al.
Publicado: (2014)

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus
por: Piha-Paul, Sarina A., et al.
Publicado: (2014)

Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials
por: Subbiah, Ishwaria M., et al.
Publicado: (2013)

Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine
por: Tsimberidou, Apostolia-Maria, et al.
Publicado: (2019)

Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer
por: Wang, Zhijie, et al.
Publicado: (2017)

Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience
por: Hou, Ming-Mo, et al.
Publicado: (2016)

FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors
por: Jardim, Denis L., et al.
Publicado: (2014)

Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer
por: Wang, Yudong, et al.
Publicado: (2018)

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway
por: Wheler, Jennifer J., et al.
Publicado: (2014)

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors
por: Tang, Chad, et al.
Publicado: (2013)

PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
por: Janku, Filip, et al.
Publicado: (2011)

Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience
por: Fu, Siqing, et al.
Publicado: (2015)

Phase 1 trial of ADI‐PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors
por: Yao, Shuyang, et al.
Publicado: (2021)

PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes
por: Janku, Filip, et al.
Publicado: (2012)

BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes
por: El-Osta, Hazem, et al.
Publicado: (2011)

Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer
por: Falchook, Gerald S., et al.
Publicado: (2013)

Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
por: Janku, Filip, et al.
Publicado: (2015)

Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
por: Janku, Filip, et al.
Publicado: (2015)

Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience
por: Wang, Zhijie, et al.
Publicado: (2016)

Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences
por: Yao, Shuyang, et al.
Publicado: (2022)

Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors
por: Subbiah, Ishwaria M., et al.
Publicado: (2018)

Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi‐arm phase Ib study
por: Thein, Kyaw Zin, et al.
Publicado: (2021)

Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
por: Thein, Kyaw Zin, et al.
Publicado: (2021)

Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials
por: Said, Rabih, et al.
Publicado: (2014)

Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience
por: Goldstein, Jennifer B., et al.
Publicado: (2017)

Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study
por: Thein, Kyaw Z., et al.
Publicado: (2022)

Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: The university of Texas MD Anderson cancer center experience
por: Corrales-Medina, Fernando F., et al.
Publicado: (2014)

Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies
por: Subbiah, Vivek, et al.
Publicado: (2016)

BRAF mutation testing with a rapid, fully integrated molecular diagnostics system
por: Janku, Filip, et al.
Publicado: (2015)

Challenges and perspective of drug repurposing strategies in early phase clinical trials
por: Kato, Shumei, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fs8ciia3kiorb60u1f4trih6hd